Metalloproteinase Gene Expression Correlates With Clinical Outcome in Dupuytren's Disease

Genome-Wide High-Resolution Screening in Dupuytren's Disease Reveals Common Regions of DNA Copy Number Alterations

“…Two CNVRs containing genes with high expression differences in tissue from patients with DD were selected for further analysis based on their biological function; these include the CNVR on chromosome 1p36, which contains matrix metallopeptidase (MMP)21/22B, and the CNVR located on chromosome 8p11 (which contains ADAM3A) ( Table 1). Both MMPs and ADAMs have been implicated in DD pathology, 23,28,29 and the CNVRs we detected were also in close proximity to other MMP and ADAM genes. Finally, CNVRs 1q31, 14q11, and 20p13 were selected for their consistently large DNA changes (amplification or deletion) seen in more than 2 patients with DD (Table 1; Fig.…”

Injectable Collagenase Clostridium Histolyticum: A New Nonsurgical Treatment for Dupuytren's Disease

“…[25][26][27] More recently, inhibition of transforming growth factor-␤1 and matrix metalloproteinase activity have been proposed as potential nonsurgical therapeutic targets for Dupuytren's disease in preclinical studies. [28][29][30][31] Collagenase C histolyticum is the first nonsurgical, office-based treatment option for Dupuytren's disease with proven efficacy and safety. The CORD studies are the largest prospective, placebo-controlled studies conducted in patients with Dupuytren's disease to date.…”

Myofibroblast Distribution in Dupuytren's Cords: Correlation With Digital Contracture

“…This would be supported by the increased expression of matrix metalloproteinases in Dupuytren's nodules and cord. [23][24][25][26] The resulting increased flexion deformity would impair function and the reduced movement at the joint would in turn lead to a reduction in tension sensed by nodular myofibroblasts. This can be considered as a form of stress shielding, which in wound healing has been shown to result in myofibroblast apoptosis after re-epithelialization.…”